和誉-B(02256.HK)：FGFR4抑制剂依帕戈替尼完成全球I期研究扩展阶段美国首例患者给药

Core Viewpoint - The company, He Yu-B (02256.HK), has successfully completed the first patient dosing in a global multicenter Phase I clinical study of its self-developed high-selectivity small molecule FGFR4 inhibitor, Irpagratinib (ABSK-011), targeting FGF19 overexpressing advanced hepatocellular carcinoma (HCC) [1] Group 1 - Irpagratinib has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA), which is expected to accelerate its global clinical development process [1]